Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer
April 23 2018 - 8:30AM
Alder Biopharmaceuticals, Inc., (NASDAQ:ALDR), a biopharmaceutical
company focused on developing novel therapeutic antibodies for the
treatment of migraine, today announced that Eric Carter, Ph.D.,
M.D., has been named Interim Chief Medical Officer, effective
immediately. His primary responsibilities will include leading the
Company through its ongoing Biologics License Application (BLA)
submission process for eptinezumab, Alder’s lead investigational
product candidate for migraine prevention, and facilitating other
clinical and commercial advancement activities. He will report
to Paul B. Cleveland, Interim President and Chief Executive
Officer. Dr. Carter has served as a consultant to the Company since
March 2018.
Dr. Carter served as Senior Vice President, Chief Medical
Officer and Global Head of Clinical & Non-Clinical Development
of Allergan Inc. from 2011 to 2015, where he led the organization
through 11 domestic and international drug candidate approvals and
managed an annual budget of approximately $700 million. With more
than 20 years of experience as a physician and as an executive in
the pharmaceutical industry, Dr. Carter has overseen the
introduction of new drug candidates into clinical development and
practice, managed complex processes and global teams and provided
support around key commercialization activities for numerous
organizations. Dr. Carter currently serves as Chairman of the
Scientific Advisory Board of Bioniz Therapeutics, a clinical-stage
biopharmaceutical company, and serves on the Board of Directors of
Adverum Biotechnologies, a public gene therapy company focused on
rare diseases. Dr. Carter received his M.D. from the University of
Miami School of Medicine and his Ph.D. in Biochemistry from the
University of Cambridge in Cambridge, England.
“Our planned BLA submission for eptinezumab remains our top
priority, and we are pleased to welcome Eric to the team as we
advance towards commercialization,” said Paul B. Cleveland. “Eric
has a proven record of success with the clinical development and
approval of major drug candidates, and we are confident Alder will
benefit from his expertise and leadership during this important
time.”
“I’m excited to join Alder and lead eptinezumab’s clinical
development program in support of the Company’s planned BLA
submission,” said Dr. Carter. “I look forward to working closely
with the Alder team and the physician community as we progress
eptinezumab towards approval, with an opportunity to provide a
treatment option for millions of migraine sufferers debilitated by
their disease.”
About Alder BioPharmaceuticals, Inc.Alder
BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company committed to transforming the treatment paradigm for
patients with migraine and other serious neurological or
inflammatory conditions. Leveraging its pioneering monoclonal
antibody technologies, Alder discovers and develops novel
therapeutic antibodies designed to deliver highly differentiated,
best-in-class clinical profiles. Alder's lead pivotal-stage product
candidate, eptinezumab, is being evaluated as potentially the
first-to-market migraine prevention infusion therapy. Eptinezumab
is a monoclonal antibody (mAb) inhibiting calcitonin gene-related
peptide (CGRP), which is believed to play a key role in mediating
and initiating migraine. Alder is additionally evaluating ALD1910,
a preclinical product candidate also in development as a migraine
prevention therapy. ALD1910 is a monoclonal antibody that inhibits
pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38),
another protein that is active in mediating the initiation of
migraine. Clazakizumab, Alder's third program, is a monoclonal
antibody candidate that inhibits interleukin-6 and is licensed
to Vitaeris, Inc. For more information, please
visit http://www.alderbio.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, without limitation, statements relating to: the
continued development and clinical, therapeutic and commercial
potential of eptinezumab; the planned BLA submission and the
potential regulatory approval of eptinezumab; the belief that
eptinezumab has the potential to be a meaningful treatment option;
and the anticipated commercialization of eptinezumab; Words such as
“will,” “planned,” “priority,” “advance,” “confident,” “support,”
“look forward,” “progress,” “opportunity,” “option,” “potential,”
or other similar expressions, identify forward-looking statements,
but the absence of these words does not necessarily mean that a
statement is not forward-looking. In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements. The
forward-looking statements in this press release are based upon
Alder's current plans, assumptions, beliefs, expectations,
estimates and projections, and involve substantial risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in the forward-looking statements
due to these risks and uncertainties as well as other factors,
which include, without limitation: risks related to the potential
failure of eptinezumab to demonstrate safety and efficacy in
clinical testing; Alder's ability to conduct clinical trials and
studies of eptinezumab sufficient to achieve a positive completion;
the availability of data at the expected times; the clinical,
therapeutic and commercial value of eptinezumab; risks and
uncertainties related to regulatory application, review and
approval processes and Alder's compliance with applicable legal and
regulatory requirements; risks and uncertainties relating to the
manufacture of eptinezumab; Alder's ability to obtain and protect
intellectual property rights, and operate without infringing on the
intellectual property rights of others; the uncertain timing and
level of expenses associated with Alder's development and
commercialization activities; the sufficiency of Alder's capital
and other resources; market competition; changes in economic and
business conditions; and other factors discussed under the caption
"Risk Factors" in Alder's Annual Report on Form 10-K for the fiscal
year ended December 31, 2017, which was filed with the Securities
and Exchange Commission (SEC) on February 26, 2018, and is
available on the SEC's website at www.sec.gov. Additional
information will also be set forth in Alder's other reports and
filings it will make with the SEC from time to time. The
forward-looking statements made in this press release speak only as
of the date of this press release. Alder expressly disclaims any
duty, obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Alder's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
Investor Relations Contact: |
|
Ashwin
Agarwal |
Michael
Schaffzin |
Vice
President, Corporate Strategy |
Stern
Investor Relations, Inc. |
Alder
Biopharmaceuticals, Inc. |
212-362-1200 |
425-408-8567 |
michael@sternir.com |
aagarwal@alderbio.com |
|
|
|
Media Contact: |
|
Andy
Brimmer / Trevor Gibbons / Aura Reinhard |
|
Joele
Frank, Wilkinson Brimmer Katcher |
|
212-355-4449 |
|
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2023 to Apr 2024